EP4547233A1 — Crystalline salts of lisdexamfetamine
Assigned to Synthimed Labs Private Ltd · Expires 2025-05-07 · 1y expired
What this patent protects
The present invention relates to pure salts of amphetamine prodrug, in particular, L-lysine-d- amphetamine (known as lisdexamfetamine) and industrial advantageous process for preparation thereof. The present invention relates to the crystalline salts of lisdexamfetamine selected …
USPTO Abstract
The present invention relates to pure salts of amphetamine prodrug, in particular, L-lysine-d- amphetamine (known as lisdexamfetamine) and industrial advantageous process for preparation thereof. The present invention relates to the crystalline salts of lisdexamfetamine selected from crystalline lisdexamphetamine dibesylate, crystalline hydrogen sulfate (Form-1 and Form-2). Further, the present invention relates to the preparation of crystalline salts of lisdexamfetamine and wherein salts are selected from dibesylate, hydrogen sulfate and difumarate.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.